Genentech: Our Pipeline

<!doctype html> <html lang="en-us" > <head> <meta charset="utf-8"> <title>Genentech: Our Pipeline</title> <meta name="description" content="Learn more about our new molecular entities (NMES) in active clinical development."> <link href="https://feeds.feedburner.com/Genentech-Stories" rel="alternate" type="application/rss+xml" title="Genentech - Read about breakthrough science, the everyday people who make it happen, and the patients we serve." /> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:title" content="Genentech: Our Pipeline" /> <meta property="og:description" content="Learn more about our new molecular entities (NMES) in active clinical development." /> <meta property="og:image" content="https://www.gene.com/assets/frontend/img/social.png" /> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@genentech"> <meta name="twitter:title" content="Genentech: Our Pipeline"> <meta name="twitter:description" content="Learn more about our new molecular entities (NMES) in active clinical development."> <meta name="twitter:creator" content="@genentech"> <meta name="twitter:image:src" content="https://www.gene.com/assets/frontend/img/social.png"> <meta name="csrf-token" content=""> <script data-icons="/assets/frontend/svg/icons.svg"></script> <link rel="preload" as="style" href="https://www.gene.com/build/assets/v3-main-site-DD6bpT6p.css" /><link rel="stylesheet" href="https://www.gene.com/build/assets/v3-main-site-DD6bpT6p.css" /> <link rel="icon" href="/assets/frontend/img/favicon.ico"> <link rel="apple-touch-icon-precomposed" href="/assets/frontend/img/apple-icon-touch.png"> <link rel="sitemap" type="application/xml" title="Sitemap" href="/sitemap" /> <link rel="stylesheet" href="https://www.gene.com/assets/frontend/css/custom/galaxySearch.css" /> <link rel="canonical" href="https://www.gene.com/medical-professionals/pipeline"> <style> .fit-vids-style { display: none; } </style> <link rel="stylesheet" href="/assets/frontend/css/custom/pipeline.css"/> <script> var jQ = { queue: [], ready: function (f) { if (typeof f=='function') jQ.queue.push(f); return jQ; }, unq: function () { for (var i = 0; i < jQ.queue.length; i++) jQ.queue[i](); jQ.queue = null; } }; if (typeof window.jQuery == 'undefined') { window.jQuery = window.$ = jQ.ready; } var Gene = { universal: {}, configs: {}, main: {}, features: {}, custom: {}, analytics: {} }; Gene.configs.paths = { prepend : '/' } </script>  <script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="0fd064ad-a247-479a-9e43-5ca8b40bcb43" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>  <script> var isReturningUser = false; if (window.localStorage) { isReturningUser = localStorage.getItem('RETURNING_USER') != null; localStorage.setItem('RETURNING_USER', true); } var referrer = 'direct'; if (document.referrer && document.referrer != "") { referrer = document.referrer; } var dataLayer = [{ 'userType': isReturningUser ? 'returning' : 'new', 'referrer': referrer, 'contentID': 'node-35ebf8e6-e83e-4a09-8810-7d272cc40597', 'contentID': 'node-35ebf8e6-e83e-4a09-8810-7d272cc40597', }]; </script> <link rel="modulepreload" href="https://www.gene.com/build/assets/analytics-standalone-YYY1jLtB.js" /><script src="https://www.gene.com/build/assets/analytics-standalone-YYY1jLtB.js"></script> <script type="text/javascript"> function getQueryParam(str) { var v = window.location.search.match(new RegExp('(?:[\?\&]'+str+'=)([^&]+)')); return v ? v[1] : null; } var src = getQueryParam('src'); if (src) { Gene.analytics.setSource('Source', src); } </script> <script src="https://cdn.jsdelivr.net/gh/alpinejs/alpine@v2.x.x/dist/alpine.min.js" defer></script> </head> <body class=" ">  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PPKDWPC');</script>   <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PPKDWPC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <header id='gene-header' class='header'></header> <div class="l-page-overlay"></div> <script> // @todo: This is temporary code - to be moved to separate file (both css & js). var relatedTranslations = []; var currentLangId = 'en'; var langSwitchLabels = {};; $(document).ready(function () { if (relatedTranslations.length > 0) { var selector = $('<select data-minimum-results-for-search="50" data-width="resolve" style="margin-top: -15px; width: 160px;"></select>'); selector.append($('<option>' + (langSwitchLabels[currentLangId] ?? currentLangId) + '</option>')); relatedTranslations.forEach(function (translation) { selector.append($('<option value="' + translation.calculated_path + '">' + (langSwitchLabels[translation.lang_id] ?? translation.lang_id) + '</option>')); }); selector.on('change', function () { if ($(this).val().length > 0) { window.location = '/switch?request_path=' + $(this).val(); } }); var breadcrumbs = $('.js-nav-container .breadcrumbs').first(); if (breadcrumbs) { var container = $('<div class="lang-switch-container" style="display: flex; flex-direction: row; justify-content: space-between; align-content: flex-start;"></div>'); container.append(breadcrumbs.clone()); container.append(selector); breadcrumbs.hide(); breadcrumbs.after(container); } } }); </script> <style> .lang-switch-container { margin-bottom: 10px; } .lang-switch-container .select2-container { position: relative; top: -13px; } .lang-switch-container .select2-container .select2-selection--single { margin-top: 0px; } .lang-switch-container .select2-container--default .select2-selection--single .select2-selection__arrow { top: -10px; } </style> <div class="ie-warning" style="display:none;"> <div class="ie-warning__container constrained"> <h2 class="ie-warning__text">Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.</h2> </div> </div>  <div class="header__spacer "></div> <div class="js-nav-container "> <script type="text/javascript"> Gene.analytics.setAudience('medical professional'); </script> <div class="constrained"> <div style="position: absolute; width: 260px; height: 100%;"> <div class="l-rail-left"> <div class="nav-secondary-container"> <nav class="nav-secondary js-nav-secondary"> <div class="nav-secondary__header "> <a class="nav-secondary__link" href="/medical-professionals">Medical Professionals</a> </div> <ul class="nav-secondary__children"> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/medical-professionals/medicines">Our Medicines & Products</a> </li> <li class="nav-secondary__child current"> <a class="nav-secondary__link" href="/medical-professionals/pipeline">Our Pipeline</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/medical-professionals/medinfo">Medical Resources</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/medical-professionals/clinical-trial-information">Clinical Trial Information</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/medical-professionals/sunshine-act-compliance">Sunshine Act Compliance</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/medical-professionals/product-security">Product Security</a> </li> </ul> </nav> </div> </div> </div> </div> <div class="constrained block-pipeline"> <div class="l-grid"> <div class="l-content-container"> <div class="l-content js-pipeline"> <div class="breadcrumbs"> <a href="/medical-professionals">Medical Professionals</a> / <a href="/medical-professionals/pipeline">Our Pipeline</a> </div> <div class="block-basic" style="max-width: 700px;"> <h1>Pipeline</h1> <p class="intro">Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.</p> <p class="intro" style="font-size: .8rem">These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.</p> </div> <div id="pipeline"></div> </div> </div> </div> </div> </div> <script>window.GeneJs = window.GeneJs || {};GeneJs.pipeline = {"indications":[{"activeState":"Active - Displays on Gene.com","molecule":"Emicizumab","otherNames":"","therapeuticArea":"Other","target":"","mechanismOfAction":"","indication":"Hemophilia A","description":"Emicizumab (RG6013, ACE910) is a bispecific monoclonal antibody designed to replace the function of activated factor VIII, an essential protein in the blood clotting process.Emicizumab was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed by Chugai, Roche and Genentech.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=emicizumab&cntry1=&state1=&recrs=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Crovalimab","otherNames":"","therapeuticArea":"Other","target":"","mechanismOfAction":"","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","description":"","phase":"III","isManagedByRoche":"","additionalInfo":"","trialsEnrolling":"","clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"IONIS-FB-LRx","otherNames":"","therapeuticArea":"Ophthalmology","target":"ASO Factor B","mechanismOfAction":"","indication":"Geographic Atrophy (GA)","description":"","phase":"II","isManagedByRoche":false,"additionalInfo":"Ionis Pharmaceuticals; Roche In-License","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Port Delivery System with ranibizumab","otherNames":"RG91213","therapeuticArea":"Ophthalmology","target":"Vascular endothelial growth factor (VEGF)","mechanismOfAction":"","indication":"Diabetic Macular Edema (DME)","description":"Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with diabetic macular edema (DME).","phase":"III","isManagedByRoche":true,"additionalInfo":"Partner with ForSight VISION4.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04108156","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Port Delivery System with ranibizumab","otherNames":"RG91213","therapeuticArea":"Ophthalmology","target":"Vascular endothelial growth factor (VEGF)","mechanismOfAction":"","indication":"Diabetic Retinopathy without DME","description":"Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with diabetic retinopathy (DR) without DME.","phase":"III","isManagedByRoche":true,"additionalInfo":"Partner with ForSight VISION4.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04503551","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6120 (VEGF-Ang2 DutaFab)","otherNames":"","therapeuticArea":"Ophthalmology","target":"Vascular endothelial growth factor (VEGF) and Angiopoietin 2 (Ang-2)","mechanismOfAction":"","indication":"wet age-related macular degeneration (AMD)","description":"RG6120 (VEGF-Ang2 DutaFab) is a bispecific Fab molecule targeting vascular endothelial growth factor (VEGF) and Angiopoietin 2 (Ang-2).","phase":"I","isManagedByRoche":true,"additionalInfo":"Built on the DutaFab platform, RG6120 is specifically designed to be compatible with the Port Delivery System.","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6179","otherNames":"","therapeuticArea":"Ophthalmology","target":"IL-6","mechanismOfAction":"","indication":"Diabetic Macular Edema (DME)","description":"Vamikibart (RG6179) is a monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine.","phase":"II","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=Diabetic+Macular+Edema&term=RO7200220&cntry=&state=&city=&dist=&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6179","otherNames":"","therapeuticArea":"Ophthalmology","target":"IL-6","mechanismOfAction":"","indication":"Uveitic Macular Edema (UME)","description":"Vamikibart (RG6179) is a monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine.","phase":"III","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05642312","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6351","otherNames":"","therapeuticArea":"Ophthalmology","target":"","mechanismOfAction":"","indication":"Retinal Disease","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development","trialsEnrolling":"","clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6501 (OpRegen)","otherNames":"","therapeuticArea":"Ophthalmology","target":"","mechanismOfAction":"","indication":"Geographic Atrophy (GA)","description":"OpRegen is a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders","phase":"II","isManagedByRoche":false,"additionalInfo":"This molecule is being developed by Genentech in partnership with Lineage Cell Therapeutics.","trialsEnrolling":true,"clinicalTrialLabel1":"Clinicaltrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05626114","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG7774","otherNames":"","therapeuticArea":"Ophthalmology","target":"","mechanismOfAction":"","indication":"Diabetic Retinopathy","description":"","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG7921","otherNames":"","therapeuticArea":"Ophthalmology","target":"","mechanismOfAction":"","indication":"wet age-related macular degeneration (AMD)","description":"","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Anti-latent TGF-beta1 (SOF10)","otherNames":"RG6440","therapeuticArea":"Oncology","target":"Latent TGF-beta1","mechanismOfAction":"","indication":"Solid tumors","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"This molecule is being developed in collaboration with Chugai.","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/search?term=RO7496353","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"AR degrader","otherNames":"RG6537, GDC-2992","therapeuticArea":"Oncology","target":"Androgen receptor (AR)","mechanismOfAction":"","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","description":"","phase":"I","isManagedByRoche":"","additionalInfo":"This molecule was licensed from Jemincare.","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/search?intr=RO7656594","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Atezolizumab","otherNames":"","therapeuticArea":"Oncology","target":"Tumor immunotherapy, programmed death ligand 1 (PD-L1)","mechanismOfAction":"","indication":"Solid tumors","description":"Anti-PDL1 (MPDL3280A, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1).","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=MPDL3280A&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Atezolizumab","otherNames":"","therapeuticArea":"Oncology","target":"Tumor immunotherapy, programmed death ligand 1 (PD-L1)","mechanismOfAction":"","indication":"Previously untreated metastatic triple negative breast cancer (IMpassion132)","description":"Anti-PDL1 (MPDL3280A, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1).","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Atezolizumab&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Atezolizumab","otherNames":"","therapeuticArea":"Oncology","target":"Tumor immunotherapy, programmed death ligand 1 (PD-L1)","mechanismOfAction":"","indication":"Neoadjuvant triple negative breast cancer (IMpassion031)","description":"Anti-PDL1 (MPDL3280A, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1).","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Atezolizumab&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Atezolizumab","otherNames":"","therapeuticArea":"Oncology","target":"Tumor immunotherapy, programmed death ligand 1 (PD-L1)","mechanismOfAction":"","indication":"Adjuvant triple negative breast cancer (IMpassion030)","description":"Anti-PDL1 (MPDL3280A, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1).","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Atezolizumab&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Autogene cevumeran","otherNames":"RG6180, RO7198457","therapeuticArea":"Oncology","target":"Messenger RNA (mRNA) based personalized cancer vaccine that targets each patient's unique neoantigens (individualized neoantigen-specific immunotherapy, iNeST)","mechanismOfAction":"","indication":"Solid tumors","description":"Autogene cevumeran (RO7198457, RG6180) is a messenger RNA (mRNA) based personalized cancer vaccine. It is an individualized therapy designed and manufactured specifically to target each cancer patient's unique neoantigens (which result from tumor-specific mutations) to elicit an immune response against that patient's tumor.","phase":"I","isManagedByRoche":false,"additionalInfo":"This program is being developed in collaboration with BioNTech.","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT03289962","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Autogene cevumeran","otherNames":"RG6180, RO7198457","therapeuticArea":"Oncology","target":"Messenger RNA (mRNA) based personalized cancer vaccine that targets each patient's unique neoantigens (individualized neoantigen-specific immunotherapy, iNeST)","mechanismOfAction":"","indication":"Advanced melanoma","description":"Autogene cevumeran (RO7198457, RG6180) is a messenger RNA (mRNA) based personalized cancer vaccine. It is an individualized therapy designed and manufactured specifically to target each cancer patient's unique neoantigens (which result from tumor-specific mutations) to elicit an immune response against that patient's tumor.","phase":"II","isManagedByRoche":false,"additionalInfo":"This program is being developed in collaboration with BioNTech.","trialsEnrolling":false,"clinicalTrialLabel1":"IMcode001","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT03815058","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Autogene cevumeran","otherNames":"RG6180, RO7198457","therapeuticArea":"Oncology","target":"Messenger RNA (mRNA) based personalized cancer vaccine that targets each patient's unique neoantigens (individualized neoantigen-specific immunotherapy, iNeST)","mechanismOfAction":"","indication":"Adjuvant pancreatic ductal adenocarcinoma (PDAC)","description":"Autogene cevumeran (RO7198457, RG6180) is a messenger RNA (mRNA) based personalized cancer vaccine. It is an individualized therapy designed and manufactured specifically to target each cancer patient's unique neoantigens (which result from tumor-specific mutations) to elicit an immune response against that patient's tumor.","phase":"II","isManagedByRoche":false,"additionalInfo":"This program is being developed in collaboration with BioNTech.","trialsEnrolling":true,"clinicalTrialLabel1":"IMcode003","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05968326","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Cevostamab","otherNames":"RG6160, BFCR4350A","therapeuticArea":"Oncology","target":"FcRH5 x CD3","mechanismOfAction":"","indication":"Relapsed or refractory multiple myeloma","description":"Cevostamab (BFCR4350A, RG6160) is a T-cell engaging bispecific antibody designed to target FcRH5 on myeloma cells and CD3 on T-cells. This dual targeting is designed to activate and redirect T-cells to attack FcRH5-expressing myeloma cells. ","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=cevostamab&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Cobimetinib","otherNames":"","therapeuticArea":"Oncology","target":"Receptor tyrosine kinase signaling, mitogen-activated protein kinase (MEK) selective inhibitor","mechanismOfAction":"","indication":"Metastatic melanoma","description":"GDC-0973 (RG7421), a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS\/RAF\/MEK\/ERK pathway, which is frequently activated in human tumors. Inappropriate activation of the MEK\/ERK pathway promotes cell growth in the absence of exogenous growth factors.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=GDC-0973&recr=Open","clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"Efbalropendekin alfa","otherNames":"RG6323, IL15\/IL15Ra-Fc, XmAb24306","therapeuticArea":"Oncology","target":"IL-15 complexed with IL-15 receptor alpha (IL-15R\u03b1)","mechanismOfAction":"","indication":"Solid tumors","description":"Efbalropendekin alfa is designed to stimulate the expansion and activation of natural killer (NK) cells and cytotoxic T cells and may present a potential new way to leverage the immune system to target cancer. ","phase":"I","isManagedByRoche":false,"additionalInfo":"This molecule is being developed in collaboration with Xencor.","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=XmAb24306&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Efbalropendekin alfa","otherNames":"RG6323, IL15\/IL15Ra-Fc, XmAb24306","therapeuticArea":"Oncology","target":"IL-15 complexed with IL-15 receptor alpha (IL-15R\u03b1)","mechanismOfAction":"","indication":"Multiple myeloma ","description":"Efbalropendekin alfa is designed to stimulate the expansion and activation of natural killer (NK) cells and cytotoxic T cells and may present a potential new way to leverage the immune system to target cancer. ","phase":"I","isManagedByRoche":false,"additionalInfo":"This molecule is being developed in collaboration with Xencor.","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=XmAb24306&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Englumafusp alfa (RG6076)","otherNames":"","therapeuticArea":"Oncology","target":"CD19-4-1BBL","mechanismOfAction":"","indication":"Heme tumors","description":"Englumafusp alfa (CD19-4-1BBL, RG6076) is a fusion protein targeting the 4-1BB ligand to cells bearing CD19 acting as an NK- and T-cell co-stimulator.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=RO7227166&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Entrectinib","otherNames":"","therapeuticArea":"Oncology","target":"Neurotropic tropomyosin receptor kinase (NTRK) gene fusions; ROS proto-oncogene 1 (ROS1) gene fusions","mechanismOfAction":"","indication":"Solid Tumors","description":"Entrectinib (RXDX-101, RG6268) is a CNS-active tyrosine-kinase inhibitor being evaluated for the potential treatment of locally advanced or metastatic tumors that harbor NTRK or ROS1 gene rearrangements.","phase":"II","isManagedByRoche":false,"additionalInfo":"This molecule was obtained through the acquisition of Ignyta.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Entrectinib+&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Entrectinib","otherNames":"","therapeuticArea":"Oncology","target":"Neurotropic tropomyosin receptor kinase (NTRK) gene fusions; ROS proto-oncogene 1 (ROS1) gene fusions","mechanismOfAction":"","indication":"Non-small cell lung cancer","description":"Entrectinib (RXDX-101, RG6268) is a CNS-active tyrosine-kinase inhibitor being evaluated for the potential treatment of locally advanced or metastatic tumors that harbor NTRK or ROS1 gene rearrangements.","phase":"II","isManagedByRoche":false,"additionalInfo":"This molecule was obtained through the acquisition of Ignyta.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Entrectinib+&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Forimtamig (RG6234)","otherNames":"","therapeuticArea":"Oncology","target":"GPRC5D X CD3","mechanismOfAction":"","indication":"Multiple myeloma","description":"GPRC5D x CD3 (RG6234) is a novel T-cell engaging bispecific antibody, targeting both GPRC5D, on the surface of plasma cells, and CD3, a component of the T-cell receptor (TCR) complex, on the surface of T cells.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=RO7425781&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Giredestrant","otherNames":"","therapeuticArea":"Oncology","target":"Selective estrogen receptor degrader","mechanismOfAction":"","indication":"Grade 1 endometrioid endometrial cancer","description":"Giredestrant (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05634499","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Inavolisib (GDC-0077)","otherNames":"","therapeuticArea":"Oncology","target":"Receptor tyrosine kinase signaling, phosphoinositide 3-kinase (PI3K) inhibitor","mechanismOfAction":"","indication":"HR+, HER2-negative, PIK3CA mutated mBC post CDK4\/6i therapy (INAVO121)","description":"Inavolisib (GDC-0077, RG6114) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K\/Akt\/mTOR pathway regulates cell growth and survival.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05646862?term=inavolisib&draw=2&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Giredestrant","otherNames":"","therapeuticArea":"Oncology","target":"Selective estrogen receptor degrader","mechanismOfAction":"","indication":"ER+ HER2-negative breast cancer, adjuvant ER+ breast cancer","description":"Giredestrant (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.","phase":"III","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03332797?cond=NCT03332797&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Giredestrant","otherNames":"","therapeuticArea":"Oncology","target":"Selective estrogen receptor degrader","mechanismOfAction":"","indication":"1L ER+ metatstatic breast cancer","description":"Giredestrant (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04546009","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Glofitamab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with bivalent binding to CD20 and monovalent binding to CD3 (2:1 format)","mechanismOfAction":"","indication":"Heme tumors","description":"Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=glofitamab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Glofitamab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with bivalent binding to CD20 and monovalent binding to CD3 (2:1 format)","mechanismOfAction":"","indication":"R\/R mantle cell lymphoma","description":"Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=glofitamab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Glofitamab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with bivalent binding to CD20 and monovalent binding to CD3 (2:1 format)","mechanismOfAction":"","indication":"1L diffuse large B-cell lymphoma","description":"Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=glofitamab&rank=1#rowId0 ","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Glofitamab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with bivalent binding to CD20 and monovalent binding to CD3 (2:1 format)","mechanismOfAction":"","indication":"2L+ diffuse large B-cell lymphoma","description":"Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=glofitamab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Inavolisib (GDC-0077)","otherNames":"","therapeuticArea":"Oncology","target":"Receptor tyrosine kinase signaling, phosphoinositide 3-kinase (PI3K) inhibitor","mechanismOfAction":"","indication":"Solid tumors and ER+ HER2-negative breast cancer","description":"Inavolisib (GDC-0077, RG6114) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K\/Akt\/mTOR pathway regulates cell growth and survival.","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03006172?term=GDC-0077&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Inavolisib (GDC-0077)","otherNames":"","therapeuticArea":"Oncology","target":"Receptor tyrosine kinase signaling, phosphoinositide 3-kinase (PI3K) inhibitor","mechanismOfAction":"","indication":"PIK3CA-mutant HR+ mBC in combination with palbociclib fulvestrant","description":"Inavolisib (GDC-0077, RG6114) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K\/Akt\/mTOR pathway regulates cell growth and survival.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04191499","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"KRAS G12C (GDC-6036)","otherNames":"","therapeuticArea":"Oncology","target":"GDC-6036 targets the mutant KRAS G12C protein. KRAS mutations are found in more than 25% of all human cancers and generate a mutant, constantly active form of the KRAS protein that results in the formation and growth of tumors. ","mechanismOfAction":"","indication":"Metastatic solid tumors with KRAS G12C mutation","description":"GDC-6036 (RG6330) is an investigational small molecule that has been shown in vitro to selectively target and block the mutant KRAS G12C protein.","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=GDC-6036&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Mosunetuzumab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format)","mechanismOfAction":"","indication":"Heme tumors","description":"Lunsumio (mosunetuzumab, anti-CD20\/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=mosunetuzumab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Mosunetuzumab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format)","mechanismOfAction":"","indication":"2L+ follicular lymphoma","description":"Lunsumio (mosunetuzumab, anti-CD20\/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=mosunetuzumab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Mosunetuzumab","otherNames":"","therapeuticArea":"Oncology","target":"CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format)","mechanismOfAction":"","indication":"2L+ diffuse large B-cell lymphoma","description":"Lunsumio (mosunetuzumab, anti-CD20\/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=mosunetuzumab&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Pertuzumab","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Early HER2-positive breast cancer in combination with trastuzumab emtansine","description":"Pertuzumab (Perjeta) is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. For Perjeta full prescribing information, including Boxed WARNINGS, Medication Guide and additional important safety information, please visit http:\/\/www.perjeta.com or call: 1-888-249-4918.","phase":"III","isManagedByRoche":true,"additionalInfo":"This study was completed and published in Lancet Oncology Jan 2021","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=pertuzumab&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Pertuzumab","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Early and metastatic HER2-positive breast cancer in combination with atezolizumab","description":"Pertuzumab (Perjeta) is a humanized monoclonal antibody designed to prevent HER2 dimerisation, a process that is believed to play an important role in the growth and formation of several different cancer types. For Perjeta full prescribing information, including Boxed WARNINGS, Medication Guide and additional important safety information, please visit http:\/\/www.perjeta.com or call: 1-888-249-4918.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=pertuzumab&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6411","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Solid tumors","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05581004","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6468","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Solid tumors","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/study\/NCT06031441","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6538","otherNames":"","therapeuticArea":"Oncology","target":"P-BCMA-ALLO1","mechanismOfAction":"","indication":"Heme tumors","description":"P-BCMA-ALLO1 (RG6538) is an off-the-shelf, donor derived, allogeneic anti-BCMA CAR T therapy with potent antitumor function for the treatment of multiple myeloma. P-BCMA-ALLO1 is produced using two key platform technologies: the nonviral piggyBac\u00ae DNA Modification System and the high-fidelity Cas-CLOVER\u2122 Site-Specific Gene Editing System delivering a high percentage of TSCM cells. P-BCMA-ALLO1 is designed to be fully allogeneic, with genetic edits to eliminate or reduce both host-vs-graft and graft-vs-host alloreactivity.","phase":"I","isManagedByRoche":true,"additionalInfo":"This molecule is being developed in collaboration with Poseida Therapeutics","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?term=P-BCMA-ALLO1&draw=2&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6540","otherNames":"","therapeuticArea":"Oncology","target":"P-CD19xCD20 - ALLO1","mechanismOfAction":"","indication":"Heme tumors","description":"P-CD19xCD20-ALLO1 is an off-the-shelf, allogeneic CAR-T cell therapy product candidate being developed for relapsed or refractory B-cell malignancies in partnership with Poseida. P-CD19xCD20-ALLO1 expresses two fully functional CAR molecules to target cells that express either CD19 or CD20. The dual targeting approach employed in P-CD19xCD20-ALLO1 aims to overcome the antigen escape limitations of CD19-only targeted CAR-T therapies by simultaneously targeting both CD19 and CD20. In addition to the dual targeting, P-CD19xCD20-ALLO1 uses a novel CD19 binder that showed greater potency in in vivo preclinical models when compared to the canonical FMC63 Single-chain variable fragment (scFv) binder.","phase":"I","isManagedByRoche":true,"additionalInfo":"This molecule is being developed in collaboration with Poseida Therapeutics","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/search?term=P-CD19CD20-ALLO1%20","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Runimotamab","otherNames":"RG6194, HER2xCD3","therapeuticArea":"Oncology","target":"T-cell engaging bispecific antibody, HER2 and CD3","mechanismOfAction":"","indication":"Metastatic HER2-expressing cancers","description":"Runimotamab (HER2xCD3, RG6194) is a T-cell engaging bispecific antibody designed to target both HER2 on cancer cells and CD3 on T-cells. This dual targeting is designed to redirect T-cells to attack HER2-expressing cancer cells.","phase":"I","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03448042?term=BTRC4017A&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Tiragolumab","otherNames":"","therapeuticArea":"Oncology","target":"T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin super family, is a novel immune inhibitory receptor","mechanismOfAction":"","indication":"Non-small cell lung cancer","description":"Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR).","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=tiragolumab&cond=Lung+Cancer&draw=2&rank=2#rowId1","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Tiragolumab","otherNames":"","therapeuticArea":"Oncology","target":"T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin super family, is a novel immune inhibitory receptor","mechanismOfAction":"","indication":"Esophageal cancer","description":"Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR).","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=tiragolumab&cond=Esophagus+Cancer&draw=2&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Tiragolumab","otherNames":"","therapeuticArea":"Oncology","target":"T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin super family, is a novel immune inhibitory receptor","mechanismOfAction":"","indication":"Squamous cell carcinoma of head and neck","description":"Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR).","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=SCCHN&term=tiragolumab&cntry=&state=&city=&dist=&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Tiragolumab","otherNames":"","therapeuticArea":"Oncology","target":"T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin super family, is a novel immune inhibitory receptor","mechanismOfAction":"","indication":"Heme & solid tumors","description":"Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR).","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=tiragolumab&cond=cervical+cancer+OR+SCCHN&draw=1&rank=2#rowId1","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"1st line HER2-positive metastatic breast cancer","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Early HER2-positive breast cancer in combination with pertuzumab","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Early and metastatic HER2-positive breast cancer in combination with atezolizumab","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"3rd line HER2-positive metastatic breast cancer","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"2L + HER-2+ PD-L1+ mBC (KATE3)","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.\r","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Trastuzumab emtansine","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"HER2-positive early breast cancer high-risk patients (ASTEFANIA)","description":"Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate that is designed to specifically target cells over expressing HER2. It is being tested in a variety of HER2 positive cancers.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"ClinicalTrials.gov","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Trastuzumab+emtansine&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Vemurafenib ","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Papillary thyroid cancer, BRAF mutation positive","description":"Vemurafenib (Zelboraf) is an oral, small molecule, BRAF kinase inhibitor. The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that keep the BRAF protein in an active state may cause excessive pathway signalling, leading to uncontrolled cell growth and survival. Please see accompanying full Prescribing Information and Medication Guide for additional important safety information.","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=vemurafenib&Search=Search","clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"Venetoclax","otherNames":"","therapeuticArea":"Oncology","target":"Bcl-2 selective inhibitor","mechanismOfAction":"","indication":"1L myelodysplastic syndromes","description":"Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance.","phase":"III","isManagedByRoche":true,"additionalInfo":"This molecule is being developed in collaboration with AbbVie.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?term=venetoclax&rank=1#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Vismodegib ","otherNames":"","therapeuticArea":"Oncology","target":"","mechanismOfAction":"","indication":"Operable basal cell carcinoma","description":"Vismodegib(Erivedge) is an oral, small molecule designed to selectively inhibit abnormal signaling in the Hedgehog pathway. It is being tested in a variety of cancers. For Erivedge full prescribing information, including Boxed WARNINGS, Medication Guide and additional important safety information, please visit http:\/\/www.erivedge.com or call 1-855-737-4834","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"http:\/\/www.clinicaltrials.gov\/ct2\/results?term=vismodegib&Search=Search","clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"trontinemab","otherNames":"","therapeuticArea":"Neuroscience","target":"Anti-amyloid beta (Abeta)","mechanismOfAction":"","indication":"Alzheimer\u2019s disease","description":"Brain shuttle gantenerumab (RG6102) technology is designed to transfer gantenerumab across the blood brain barrier and increase antibody concentrations in the brain.","phase":"II","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04639050?term=RO+7126209&recrs=abcdf&fund=2&draw=2&rank=1","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Fenebrutinib","otherNames":"","therapeuticArea":"Neuroscience","target":"Bruton kinase inhibitor (BTKi)","mechanismOfAction":"","indication":"Relapsing Multiple Sclerosis","description":"Fenebrutinib (RG7845) is an investigational oral medicine, designed to be a highly selective and reversible Bruton\u2019s tyrosine kinase inhibitor (BTKi) that reduces both B-cell and myeloid lineage-cell activation.","phase":"III","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Fenebrutinib+OR+RG7845&cntry=&state=&city=&dist=&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Fenebrutinib","otherNames":"","therapeuticArea":"Neuroscience","target":"Bruton kinase inhibitor (BTKi)","mechanismOfAction":"","indication":"Primary Progressive Multiple Sclerosis","description":"Fenebrutinib (RG7845) is an investigational oral medicine, designed to be a highly selective and reversible Bruton\u2019s tyrosine kinase inhibitor (BTKi) that reduces both B-cell and myeloid lineage-cell activation.","phase":"III","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Fenebrutinib+OR+RG7845&cntry=&state=&city=&dist=&Search=Search","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Prasinezumab","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Parkinson\u2019s disease","description":"Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease (PD).","phase":"II","isManagedByRoche":false,"additionalInfo":"Managed by Pharma Research and Early Development. This molecule is being developed in collaboration with Prothena.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=prasinezumab&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6163","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Psychiatric disorders","description":"","phase":"I","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6182","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Neurodegenerative diseases","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Pharma Research and Early Development.","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6237","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Neuromuscular disorders","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Pharma Research and Early Development.","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Delandistrogene Moxeparvovec (SRP-9001)","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Duchenne Muscular Dystrophy","description":"","phase":"III","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Tominersen","otherNames":"","therapeuticArea":"Neuroscience","target":"Antisense oligonucleotide (ASO)","mechanismOfAction":"","indication":"Early \/ Prodromal Huntington\u2019s disease","description":"Tominersen (RG6042) is an antisense oligonucleotide (ASO) designed to target the underlying cause of Huntington's disease (HD) by limiting production and lowering the levels of mutant huntingtin protein (HTT ASO), a toxic protein that causes brain cell death.","phase":"II","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group. This molecule is being developed in collaboration with Ionis.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05686551?term=Roche&cond=Huntington%20Disease&rank=4","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Brainshuttle (BS)-CD20 - multiple sclerosis","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Multiple Sclerosis","description":"","phase":"I","isManagedByRoche":true,"additionalInfo":"Managed by Roche Group.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6035, RO7121932 Brain Shuttle CD20 inhibitor ","otherNames":"","therapeuticArea":"Neuroscience","target":"anti-CD20","mechanismOfAction":"","indication":"Primary Progressive Multiple Sclerosis","description":"Brain shuttle technology to transferAnti-CD20 antibody across the blood brain barrier and increase antibody concentrations in the brain\/CNS","phase":"I","isManagedByRoche":true,"additionalInfo":"Managed by Pharma Research and Early Development.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6289","otherNames":"","therapeuticArea":"Neuroscience","target":"","mechanismOfAction":"","indication":"Alzheimer's Disease","description":"","phase":"I","isManagedByRoche":"","additionalInfo":"Managed by Pharma Research and Early Development.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"tenecteplase","otherNames":"TNKase","therapeuticArea":"Neuroscience","target":"Tenecteplase is a tissue plasmingogen activator being evaluated to treat acute ischemic stroke (AIS); tenecteplase is currently FDA-approved to treat acute ST elevation myocardial infarction (STEMI). The FDA has accepted and is reviewing the AcT study data package for a potential\nindication for tenecteplase in the 0-4.5 hour time window for AIS.\n\nGenentech and Roche are responsible for TNKase (tenecteplase) in North America and Boehringer Ingelheim is responsible for the supply and marketing of Metalyse (tenecteplase) outside North America and Japan.\n\n","mechanismOfAction":"Tissue plasminogen activator","indication":"acute ischemic stroke (AIS)","description":"","phase":"III","isManagedByRoche":false,"additionalInfo":"","trialsEnrolling":false,"clinicalTrialLabel1":"Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (AcT)\n","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/study\/NCT03889249?intr=tenecteplase&term=AcT&rank=1","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Baloxavir marboxil","otherNames":"","therapeuticArea":"Infectious Disease","target":"Cap-dependent endonuclease inhibitor","mechanismOfAction":"","indication":"Influenza in children ages 1 and older","description":"Baloxavir marboxil (S-033188, RG6152), a small molecule cap-dependent endonuclease inhibitor, is being evaluated for the potential treatment of seasonal influenza A and B viruses.","phase":"III","isManagedByRoche":true,"additionalInfo":"This molecule is being developed in collaboration with Shionogi Co.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=Baloxavir+&cntry=&state=&city=&dist=","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"rhPentraxin-2","otherNames":"","therapeuticArea":"Infectious Disease","target":"Recombinant human innate immunity protein pentraxin-2 ","mechanismOfAction":"","indication":"Myelofibrosis","description":"","phase":"II","isManagedByRoche":null,"additionalInfo":null,"trialsEnrolling":null,"clinicalTrialLabel1":null,"clinicalTrialLink1":null,"clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"RG6436","otherNames":"","therapeuticArea":"Infectious Disease","target":"LepB Inhibitor","mechanismOfAction":"","indication":"Complicated urinary tract infection","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development. ","trialsEnrolling":null,"clinicalTrialLabel1":null,"clinicalTrialLink1":null,"clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"Baloxavir marboxil","otherNames":"","therapeuticArea":"Infectious Disease","target":"","mechanismOfAction":"","indication":"Reduction of transmission of influenza in households","description":"Baloxavir marboxil (S-033188, RG6152), a small molecule cap-dependent endonuclease inhibitor, is being evaluated for the potential treatment of seasonal influenza A and B viruses.","phase":"III","isManagedByRoche":true,"additionalInfo":"This molecule is being developed in collaboration with Shionogi Co.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/search?term=Baloxavir%20","clinicalTrialLabel2":null,"clinicalTrialLink2":null,"clinicalTrialLabel3":null,"clinicalTrialLink3":null},{"activeState":"Active - Displays on Gene.com","molecule":"Astegolimab","otherNames":"","therapeuticArea":"Immunology","target":"ST2 receptor; Interleukin-33 (IL-33)","mechanismOfAction":"","indication":"Chronic Obstructive Pulmonary Disease","description":"Anti-ST2 (MSTT1041A, AMG 282, RG6149) is a fully human monoclonal antibody designed to inhibit binding of interleukin-33 (IL-33) to the ST2 receptor.","phase":"III","isManagedByRoche":false,"additionalInfo":"This molecule was in-licensed from Amgen.","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Gazyva","otherNames":"","therapeuticArea":"Immunology","target":"CD20 monoclonal antibody","mechanismOfAction":"","indication":"Systemic lupus erythematosus","description":"Gazyva\/Gazyvaro (obinutuzumab, RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera\/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/search?term=gazyva","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Mosunetuzumab","otherNames":"","therapeuticArea":"Immunology","target":"CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format)","mechanismOfAction":"","indication":"Systemic lupus erythematosus","description":"Lunsumio (mosunetuzumab, anti-CD20\/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells.","phase":"I","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/search?term=mosunetuzumab#rowId0","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Obinutuzumab ","otherNames":"","therapeuticArea":"Immunology","target":"","mechanismOfAction":"","indication":"Lupus nephritis","description":"Obinutuzumab, GA101, is a glycoengineered, type II, humanized anti-CD20 monoclonal antibody.","phase":"III","isManagedByRoche":true,"additionalInfo":"","trialsEnrolling":true,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02550652?term=obinutuzumab+lupus&rank=2","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"Omalizumab","otherNames":"","therapeuticArea":"Immunology","target":"anti-IgE antibody","mechanismOfAction":"","indication":"Food Allergies","description":"Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively binds to human immunoglobulin E (IgE)","phase":"III","isManagedByRoche":false,"additionalInfo":"This molecule is being developed in collaboration with Novartis","trialsEnrolling":false,"clinicalTrialLabel1":"","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03881696","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6287","otherNames":"","therapeuticArea":"Immunology","target":"","mechanismOfAction":"","indication":"Acute graft versus host disease (aGVHD)","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development","trialsEnrolling":"","clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6315","otherNames":"","therapeuticArea":"Immunology","target":"","mechanismOfAction":"","indication":"Immunologic Disorders","description":"","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development","trialsEnrolling":true,"clinicalTrialLabel1":"Clinicaltrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05462522","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6536 (Vixarelimab)","otherNames":"","therapeuticArea":"Immunology","target":"","mechanismOfAction":"","indication":"Idiopathic pulmonary fibrosis \/ Systemic sclerosis-associated interstitial lung disease (IPF & SSc-ILD)","description":"Vixarelimab (RG6536) is a selective OSMR\u03b2-targeting, fully human monoclonal antibody that blocks OSM and IL-31 signaling while preserving signaling through the LIFR pathway. Dysregulation of OSM and\/or OSMR\u03b2 is observed in multiple human diseases and may drive fibrosis, inflammation, and other pathological processes in affected tissue.","phase":"II","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development. In-licensed from Kiniksa Pharmaceuticals.","trialsEnrolling":true,"clinicalTrialLabel1":"Clinicaltrials.gov","clinicalTrialLink1":"https:\/\/clinicaltrials.gov\/study\/NCT05785624","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""},{"activeState":"Active - Displays on Gene.com","molecule":"RG6421","otherNames":"","therapeuticArea":"Immunology","target":"","mechanismOfAction":"","indication":"Cystic Fibrosis","description":"TMEM16A Potentiator","phase":"I","isManagedByRoche":false,"additionalInfo":"Managed by Genentech Research and Early Development. Acquired from Enterprise Therapeutics.","trialsEnrolling":"","clinicalTrialLabel1":"","clinicalTrialLink1":"","clinicalTrialLabel2":"","clinicalTrialLink2":"","clinicalTrialLabel3":"","clinicalTrialLink3":""}]};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.currentNode = {"rootNode":{"id":"59bd7ce6-7a93-4a5b-8ce4-2044dbb5ce7e","parent_id":"0","title":"Medical Professionals","node_type":"static","request_path":"medical-professionals","lang_id":"en","source_translation_id":"86c029be-f08c-11ed-82a4-0242ac150003","target_id":null,"target_path":"","meta_description":"Innovative clinical science. Improved patient care.","url_suffix":"","position":25,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":"","include_js":"","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2019-05-23T21:55:15.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.secondaryNavNode = {"title":"Our Pipeline","requestPath":"medical-professionals\/pipeline","ancestors":[{"id":"59bd7ce6-7a93-4a5b-8ce4-2044dbb5ce7e","parent_id":"0","title":"Medical Professionals","node_type":"static","request_path":"medical-professionals","lang_id":"en","source_translation_id":"86c029be-f08c-11ed-82a4-0242ac150003","target_id":null,"target_path":"","meta_description":"Innovative clinical science. Improved patient care.","url_suffix":"","position":25,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":"","include_js":"","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2019-05-23T21:55:15.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}],"shouldShow":true};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.geneHeader = {"topNavNodes":{"2":{"id":"033e314b-6cfd-4977-9449-383a7a165faa","parent_id":"0","title":"Patients","node_type":"static","request_path":"patients","lang_id":"en","source_translation_id":"86a3164e-f08c-11ed-9d94-0242ac150003","target_id":null,"target_path":"","meta_description":"Learn more about our medicines, get help with coverage, and find the right resources for you.","url_suffix":"","position":6,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-08-25T22:26:19.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"8":{"id":"59bd7ce6-7a93-4a5b-8ce4-2044dbb5ce7e","parent_id":"0","title":"Medical Professionals","node_type":"static","request_path":"medical-professionals","lang_id":"en","source_translation_id":"86c029be-f08c-11ed-82a4-0242ac150003","target_id":null,"target_path":"","meta_description":"Innovative clinical science. Improved patient care.","url_suffix":"","position":25,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":"","include_js":"","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2019-05-23T21:55:15.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"11":{"id":"982193bc-a3aa-11e7-b779-d0431ef1c812","parent_id":"0","title":"Partners","node_type":"blocks","request_path":"partners","lang_id":"en","source_translation_id":"86cf2608-f08c-11ed-a8ab-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":32,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2017-09-28T00:37:55.000000Z","added_by":"admin","updated_date":"2020-02-25T13:02:07.000000Z","header_image":"","body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"12":{"id":"af5bc686-e327-4030-ade9-a30b7cdde115","parent_id":"0","title":"Scientists","node_type":"blocks","request_path":"scientists","lang_id":"en","source_translation_id":"86d36bd2-f08c-11ed-a4c0-0242ac150003","target_id":null,"target_path":"","meta_description":"Every day our scientists do the work, the relentless incremental labor that could lead to world-changing, life-changing advances.","url_suffix":"","position":38,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-03-31T23:54:11.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"14":{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":41,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"16":{"id":"c42ede74-e262-422c-aecd-bce16e4a6201","parent_id":"0","title":"Good","node_type":"blocks","request_path":"good","lang_id":"en","source_translation_id":"86d8438c-f08c-11ed-b055-0242ac150003","target_id":null,"target_path":"","meta_description":"Through the everyday, incremental acts of kindness, we can make great things happen for our communities and our patients.","url_suffix":"","position":43,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2020-05-12T02:58:56.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"19":{"id":"e2b7db24-3c44-11e8-b243-d0431ef1c812","parent_id":"0","title":"Hiring","node_type":"blocks","request_path":"careers","lang_id":"en","source_translation_id":"86dffcc6-f08c-11ed-bb3a-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":55,"prefix":"Now","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2018-04-10T05:25:19.000000Z","added_by":"admin","updated_date":"2020-07-23T22:52:27.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0}}};</script><div class="primary-footer js-nav-footer clearfix"> <div class="constrained"> <div class="footer-logo-narrow" data-set="footer-logo"> <svg aria-label="Genentech - A Member of the Roche Group"> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-genentech-logo"></use> </svg> </div> <nav class="footer-sitemap"> <ul> <li class="first-level"> <a href="/patients">For Patients</a> </li> <li> <a href="/patients/medicines">Our Medicines</a> </li> <li> <a href="/patients/patient-foundation">Genentech Patient Foundation</a> </li> <li> <a href="/patients/clinical-trials">Clinical Trials</a> </li> <li> <a href="/patients/patient-support-services">Patient Support Services</a> </li> <li> <a href="/patients/understanding-insurance">Understanding Insurance</a> </li> <li> <a href="/patients/medicine-information-support">Medicine Information Support</a> </li> <li> <a href="/patients/giving-patients-a-voice">Giving Patients a Voice</a> </li> <li> <a href="/patients/disease-education">Disease Education</a> </li> </ul> <ul> <li class="first-level"> <a href="/about-us"> About Us</a> </li> <li> <a href="/about-us/leadership">Leadership</a> </li> <li> <a href="/about-us/our-promise">Our Promise</a> </li> <li> <a href="/about-us/policy-advocacy">Policy & Advocacy</a> </li> <li> <a href="/about-us/oncology">Our Focus on Oncology</a> </li> <li> <a href="/about-us/neuroscience">Our Focus on Neuroscience</a> </li> <li> <a href="/about-us/ophthalmology">Our Focus on Ophthalmology</a> </li> <li> <a href="/about-us/awards-recognition">Awards & Recognition</a> </li> <li> <a href="/about-us/investors">Investors</a> </li> <li> <a href="/about-us/suppliers">Suppliers</a> </li> <li> <a href="/about-us/california-transparency-law">CA Transparency in Supply </a> </li> <li> <a href="/about-us/compliance">Compliance Overview</a> </li> </ul> <ul> <li class="first-level"> <a href="/contact-us"> Contact Us</a> </li> <li> <a href="/contact-us/call-us">Call Us</a> </li> <li> <a href="/contact-us/email-us">Email Us</a> </li> <li> <a href="/contact-us/visit-us">Visit Us</a> </li> <li> <a href="/contact-us/submit-medical-inquiry">Submit a Medical Inquiry</a> </li> <li> <a href="/contact-us/submit-media-inquiry">Submit a Media Inquiry</a> </li> </ul> <ul> <li class="first-level"> <a href="/medical-professionals">For Medical Professionals</a> </li> <li> <a href="/medical-professionals/medicines">Our Medicines & Products</a> </li> <li> <a href="/medical-professionals/pipeline">Our Pipeline</a> </li> <li> <a href="/medical-professionals/medinfo">Medical Resources</a> </li> <li> <a href="/medical-professionals/clinical-trial-information">Clinical Trial Information</a> </li> <li> <a href="/medical-professionals/sunshine-act-compliance">Sunshine Act Compliance</a> </li> <li> <a href="/medical-professionals/product-security">Product Security</a> </li> </ul> <ul> <li class="first-level"> <a href="/partners">For Partners</a> </li> <li> <a href="/partners/our-approach">Our Approach</a> </li> <li> <a href="/partners/what-we-are-looking-for">What We Are Looking For</a> </li> <li> <a href="/partners/partner-with-us">Partner With Us</a> </li> <li> <a href="/partners/contacts">Contact Us</a> </li> <li> <a href="/partners/our-stories">Our Stories</a> </li> </ul> <ul> <li class="first-level"> <a href="/scientists">For Scientists</a> </li> <li> <a href="/scientists/our-scientists">Our Scientists</a> </li> <li> <a href="/scientists/our-pipeline">Our Pipeline</a> </li> <li> <a href="/scientists/behind-the-science">Our Stories</a> </li> <li> <a href="/scientists/our-podcast">Our Podcast</a> </li> <li> <a href="/scientists/publications">Publications</a> </li> <li> <a href="/scientists/mta">MTA Program</a> </li> </ul> <ul> <li class="first-level"> <a href="/media">For Media</a> </li> <li> <a href="/media/news-features">News Features</a> </li> <li> <a href="/media/press-releases">Press Releases</a> </li> <li> <a href="/media/statements">Statements</a> </li> <li> <a href="/media/company-information">Company Information</a> </li> <li> <a href="/media/news-alerts">Sign Up For News Alerts</a> </li> </ul> <ul> <li class="first-level"> <a href="/good">For Good</a> </li> <li> <a href="/good/giving">Giving</a> </li> <li> <a href="/good/diversity-inclusion">Diversity & Inclusion</a> </li> <li> <a href="/good/sustainability">Sustainability</a> </li> </ul> <ul> <li class="first-level"> <a href="/diversity-inclusion"> Diversity & Inclusion</a> </li> <li> <a href="/diversity-inclusion/advancing-inclusive-research">Advancing Inclusive Research</a> </li> <li> <a href="/diversity-inclusion/health-equity">Health Equity</a> </li> <li> <a href="/diversity-inclusion/fostering-belonging">Fostering Belonging</a> </li> <li> <a href="/diversity-inclusion/transforming-society">Transforming Society</a> </li> <li> <a href="/diversity-inclusion/di-report">Our Diversity & Inclusion Report</a> </li> </ul> <ul> <li class="first-level"> <a href="/careers">Now Hiring</a> </li> <li> <a href="/careers/find-a-job">Find A Job</a> </li> <li> <a href="/careers/professional-areas">Professional Areas</a> </li> </ul> <ul> <li class="first-level"> <a>—</a> </li> <li><button id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</button></li> <li><a href="/privacy-policy">Privacy Policy</a></li> <li><a href="/wa-consumer-health-data-privacy-policy">WA Consumer Health Data Privacy Policy</a></li> <li><a href="/terms-conditions">Terms & Conditions</a></li> <li><a href="/accessibility">Accessibility</a></li> </ul> </nav> </div> <div class="constrained"> <div class="footer-social"> <div class="footer-social-list"> <a href="//facebook.com/genentech" target="_blank" data-service="facebook"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-facebook"></use> </svg> </a> <a href="//twitter.com/genentech" target="_blank" data-service="twitter"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-twitter"></use> </svg> </a> <a href="//linkedin.com/company/genentech" target="_blank" data-service="linkedin"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-linkedin"></use> </svg> </a> <a href="//youtube.com/genentech" target="_blank" data-service="youtube" style="padding: 5% 0%;"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-youtube"></use> </svg> </a> <a href="//pinterest.com/genentech" target="_blank" data-service="pinterest"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-pinterest"></use> </svg> </a> <a target="_blank" href="https://www.glassdoor.com/Overview/Working-at-Genentech-EI_IE274.11,20.htm" style="display: flex; align-items: center;"> <svg style="height: 22px;"> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-glassdoor" data-service="glassdoor"></use> </svg> </a> <a href="//instagram.com/genentech" target="_blank" data-service="instagram"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-instagram"></use> </svg> </a> </div> </div> </div> <div class="constrained"> <div class="copyright">© 2024 Genentech, Inc. All rights reserved. This site is intended for US residents only.</div> </div> </div> <link rel="modulepreload" href="https://www.gene.com/build/assets/header-DyYXM6Vv.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/index-OaaOytLl.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-BosuxZz1.js" /><script type="module" src="https://www.gene.com/build/assets/header-DyYXM6Vv.js"></script> <script type="text/javascript" src="https://www.gene.com/assets/frontend/js/custom/galaxySearch.js"></script> <script src="/assets/frontend/js/vendor/jquery-1.7.2.min.js"></script> <script src="/assets/frontend/js/vendor/select2/dist/js/select2.full.min.js"></script> <script src="/assets/frontend/js/vendor/magnific-popup/dist/jquery.magnific-popup.min.js"></script> <script src="/assets/frontend/js/vendor/FitText.js/jquery.fittext.js"></script> <link rel="preload" as="style" href="https://www.gene.com/build/assets/main-site-DPpHmyQP.css" /><link rel="modulepreload" href="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/main-site-Cl_9bscq.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-BosuxZz1.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/base-component-o8ldAQHQ.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/window-events-B7aJfebw.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/product-select-Q4_aKJ6E.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js" /><link rel="stylesheet" href="https://www.gene.com/build/assets/main-site-DPpHmyQP.css" /><script type="module" src="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js"></script><script type="module" src="https://www.gene.com/build/assets/main-site-Cl_9bscq.js"></script><script type="module" src="https://www.gene.com/build/assets/product-select-Q4_aKJ6E.js"></script><script type="module" src="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js"></script> <script src="/assets/frontend/js/custom/pipeline.js"></script> <script> jQ.unq(); jQuery(function() { // Initialize custom classes for (var classname in Gene.custom) { if (classname != 'configs') { Gene.custom[classname].init(); } } }); </script> <script src="/assets/frontend/js/custom/pipeline.js"></script> </body> </html>

CINXE.COM

Genentech: Our Pipeline